A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in
healthy adult participants
- Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in
adult patients with gout
- Part C: Evaluate the safety, tolerability and efficacy of ALN-XDH as add-on therapy in
adult patients with gout